# New Technologies for Accelerating the Discovery and Characterization of Neuroactives that Address Substance Use Disorders

> **NIH NIH DP1** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $484,500

## Abstract

ABSTRACT
 Over the last decade, there has been a dramatic increase in deaths resulting from drug overdoses.
Pharmacological interventions have proven to be transformative and life-saving in substance use disorders,
particularly in opioid addictions and overdoses. Today, there is an increasing interest in having an
armamentarium at clinician's disposal to address substance use disorders. There are three therapeutic classes
of drugs that are highly sought: alternatives, attenuators, and antidotes. Having alternative therapeutic
avenues for pain management other than opioids could help lower new addiction cases. For alternatives, we
look to anesthetics that maintain analgesic effects at sub-anesthetic concentrations. For attenuators, we seek
behavior-modifying drugs like ketamine and dizocilpine that have demonstrated reduced self-administration of
drugs of abuse like cocaine, alcohol, methamphetamine, morphine, and nicotine in animal models. As a final
line of defense, we endeavor to discover new drug overdose antidotes that reverse the toxicity of abused
drugs. The discovery of novel chemical matter in these therapeutic classes could lead towards the
development of new pharmacotherapies for treating addictions, but pharmacological modification of addictive
behaviors in mammalian models is costly and challenging to evaluate.
 The objective of this proposal is to accelerate the discovery and characterization of novel small
molecules affecting behavior using high-throughput screening of compounds in live animals guided by
behavioral profiling as opposed to biochemical or cell-based assays. Our work exploits an automated
technological platform in which the behaviors of hundreds of larval zebrafish under the influence of neuroactive
compounds can be assessed and compared simultaneously. It enables the high-throughput screening of
thousands of compounds for those that phenocopy neuroactive drugs of interest. The central premise of our
approach is that pharmacological modulation by these therapeutic classes, their unique behavioral changes in
larval zebrafish, and the identification of new related pharmacology are inter-connected. Accordingly, we
predict that molecules that phenocopy anesthetics, ketamine, or the PQs ability to reverse benzodiazepine
sedation will be new chemical matter for alternatives, attenuators, and antidotes of abused drugs. From this
perspective, we can use the high-throughput behavioral assays in larval zebrafish as a primary screen of a
structurally diverse set of >100,000 compounds. Importantly, from initial pilot screens we already have new
chemical matter of all these classes in hand. We will perform mechanistic studies using state-of-the-art imaging
of the zebrafish central nervous system to help further characterize new pharmacology. An essential part of the
work is the translation of newly discovered neuroactives into rodent models of pain and substance use
disorders.

## Key facts

- **NIH application ID:** 10789942
- **Project number:** 5DP1DA058350-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Matthew N McCarroll
- **Activity code:** DP1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $484,500
- **Award type:** 5
- **Project period:** 2023-04-01 → 2028-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10789942

## Citation

> US National Institutes of Health, RePORTER application 10789942, New Technologies for Accelerating the Discovery and Characterization of Neuroactives that Address Substance Use Disorders (5DP1DA058350-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10789942. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*